760 Parkside Avenue
Downstate Biotechnology Incubator, Suite 217
AzurRx BioPharma, Inc. aims to become a leader in developing non-systemic, recombinant protein therapies for the treatment of gastrointestinal diseases and related conditions. MS1819 recombinant lipase for exocrine pancreatic insufficiency is the company’s lead development program, and additional early stage research is being conducted for the prevention of hospital-acquired infection. The company is headquartered in Brooklyn, NY, with scientific operations based in Langlade, France.
CEO: Thijs Spoor
CSO: Daniel Dupret
Please click here for clinical trial information.